Key Highlights
- AusperBio raises $37 million in Series A financing.
- Funding supports AHB-137 clinical development and Med-Oligo™ platform.
- Led by InnoPinnacle Fund with new investors Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital, and Genesis Capital.
- AHB-137 undergoing Phase 1b trial internationally and Phase 2 trial in China.
- Breakthrough Therapy Designation from China’s CDE enhances AHB-137’s development.
Source: PR Newswire
Notable Quote
- “We are immensely grateful for the continued support from our existing investors and are very pleased to welcome new investors to the company. This financing round represents a significant milestone that recognizes our scientific and clinical achievements to date. The shared commitment from our investors to developing new therapeutics for CHB patients is truly inspiring. With this funding, together with the recent Breakthrough Therapy Designation (BTD) from China’s CDE, we are well-positioned to rapidly advance the clinical development of AHB-137 and move closer to providing a vital new treatment option for patients with CHB.” — Dr. Guofeng Cheng, CEO at AusperBio
SoHC's Take
AusperBio’s successful $37 million Series A financing marks a pivotal step in the advancement of their novel chronic hepatitis B treatment, AHB-137. This funding not only accelerates the clinical trials but also bolsters the development of their innovative Med-Oligo™ technology platform. The significant support from both existing and new investors underscores the confidence in AusperBio’s potential to deliver groundbreaking therapies. With the added momentum from China’s CDE Breakthrough Therapy Designation, AusperBio is well on its way to making a substantial impact in the fight against chronic hepatitis B, offering hope for a functional cure.
